HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Valacyclovir and prednisolone treatment for Bell's palsy: a multicenter, randomized, placebo-controlled study.

AbstractOBJECTIVE:
To investigate the effects of valacyclovir and prednisolone in comparison with those of placebo and prednisolone for the treatment of Bell's palsy, excluding zoster sine herpete.
STUDY DESIGN:
Prospective, multicenter, randomized placebo-controlled study.
SETTING:
Six academic tertiary referral centers.
PATIENTS:
Ultimately, 221 patients with Bell's palsy who were treated within 7 days of the onset. Serological and polymerase chain reaction examinations were performed to distinguish Bell's palsy from zoster sine herpete.
INTERVENTION:
The patients were treated with either valacyclovir (dosage, 1,000 mg/d for 5 days) plus prednisolone (VP [n = 114]) or placebo plus prednisolone (PP [n = 107]) administered orally.
MAIN OUTCOME MEASURE:
Recovery from the palsy was defined as a score higher than 36 using Yanagihara 40-point scoring system without facial contracture or synkinesis. The patients were followed up until complete recovery occurred or for more than 6 months in cases with a poor prognosis.
RESULTS:
The overall rate of patient recovery among those treated with VP (96.5%) was significantly better (p < 0.05) than the rate among those treated with PP (89.7%). The rate of patient recovery was also analyzed by classifying the initial severity of facial palsy. In cases of complete or severe palsy, the rates of patients treated with VP and PP who recovered were 95.7% (n = 92) and 86.6% (n = 82), respectively; the recovery rate for treatment with VP was significantly better than that with PP (p < 0.05).
CONCLUSION:
The valacyclovir and prednisolone therapy was more effective in treating Bell's palsy, excluding zoster sine herpete, than the conventional prednisolone therapy. To our knowledge, this is the first controlled study of an antiviral agent in the treatment of a sufficient number of Bell's palsy cases based on an etiologic background.
AuthorsNaohito Hato, Hiroyuki Yamada, Hisashi Kohno, Shuichi Matsumoto, Nobumitsu Honda, Kiyofumi Gyo, Satoshi Fukuda, Yasushi Furuta, Fumio Ohtani, Hiroshi Aizawa, Masaru Aoyagi, Hiroo Inamura, Tsutomu Nakashima, Seiichi Nakata, Shingo Murakami, Jun Kiguchi, Koji Yamano, Taizo Takeda, Masashi Hamada, Kazuhiro Yamakawa
JournalOtology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology (Otol Neurotol) Vol. 28 Issue 3 Pg. 408-13 (Apr 2007) ISSN: 1531-7129 [Print] United States
PMID17414047 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antiviral Agents
  • Prednisolone
  • Valine
  • Valacyclovir
  • Acyclovir
Topics
  • Acyclovir (analogs & derivatives, therapeutic use)
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antiviral Agents (therapeutic use)
  • Bell Palsy (diagnosis, drug therapy)
  • Diagnosis, Differential
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Humans
  • Male
  • Middle Aged
  • Prednisolone (therapeutic use)
  • Severity of Illness Index
  • Valacyclovir
  • Valine (analogs & derivatives, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: